Anapen® Registered for Marketing in Australia

by / Tuesday, 28 October 2008 / Published in News

SYDNEY, NSW, OCTOBER 28, 2008. LINK Pharma, a specialist Australian-owned pharmaceutical company, is pleased to announce that the Anapen® adrenaline auto-injector has been approved for marketing in Australia. LINK has been working towards providing an alternative adrenaline auto-injector device for the many Australians who may be at risk of anaphylaxis. The registration of Anapen® in Australia brings LINK Pharma a step closer to this goal. The launch of Anapen® represents the first stage in the roll out of a new LINK Immunology Business Unit with further product launches planned. The recently announced distribution partnership with the French Immunotherapy company Stallergenes will be included in this Business Unit and will commence operation on 1st December 2008.

Anapen® has been successfully launched in 14 countries in Europe and North America. LINK is proud to be the first company to launch Anapen® in the Southern Hemisphere. LINK will be launching both Anapen® 300µg and Anapen® Junior 150µg early in 2009 and the company is looking to work closely with ASCIA, the immunology profession, Anaphylaxis Australia and other relevant stakeholders to ensure the product is marketed within a strong framework of patient education.

LINK’s new Immunology Business Unit is headed by Sales & Marketing Manager, Mr. Kenneth Allan with Ms. Sabrina de Miranda stepping into the Product Management role. Healthcare providers can obtain further information on Anapen,® it’s mechanism of action and the Anapen® training device at